Sagimet Biosciences (SGMT) Liabilities and Shareholders Equity: 2023-2024
Historic Liabilities and Shareholders Equity for Sagimet Biosciences (SGMT) over the last 2 years, with Sep 2024 value amounting to $174.8 million.
- Sagimet Biosciences' Liabilities and Shareholders Equity rose 69.81% to $174.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $655.0 million, marking a year-over-year change of. This contributed to the annual value of $96.7 million for FY2023, which is N/A change from last year.
- According to the latest figures from Q3 2024, Sagimet Biosciences' Liabilities and Shareholders Equity is $174.8 million, which was down 7.54% from $189.0 million recorded in Q2 2024.
- Sagimet Biosciences' 5-year Liabilities and Shareholders Equity high stood at $194.5 million for Q1 2024, and its period low was $21.5 million during Q2 2023.
- For the 2-year period, Sagimet Biosciences' Liabilities and Shareholders Equity averaged around $129.9 million, with its median value being $138.8 million (2023).
- Data for Sagimet Biosciences' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 779.24% (in 2024) over the last 5 years.
- Quarterly analysis of 2 years shows Sagimet Biosciences' Liabilities and Shareholders Equity stood at $96.7 million in 2023, then skyrocketed by 69.81% to $174.8 million in 2024.
- Its Liabilities and Shareholders Equity stands at $174.8 million for Q3 2024, versus $189.0 million for Q2 2024 and $194.5 million for Q1 2024.